Cargando…
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,
PROteolysis-TArgeting Chimeras (PROTACs) have emerged as an innovative drug development platform. However, most PROTACs have been generated empirically because many determinants of PROTAC specificity and activity remain elusive. Through computational modelling of the entire NEDD8-VHL Cullin RING E3...
Autores principales: | Lv, Dongwen, Pal, Pratik, Liu, Xingui, Jia, Yannan, Thummuri, Dinesh, Zhang, Peiyi, Hu, Wanyi, Pei, Jing, Zhang, Qi, Zhou, Shuo, Khan, Sajid, Zhang, Xuan, Hua, Nan, Yang, Qingping, Arango, Sebastian, Zhang, Weizhou, Nayak, Digant, Olsen, Shaun K., Weintraub, Susan T., Hromas, Robert, Konopleva, Marina, Yuan, Yaxia, Zheng, Guangrong, Zhou, Daohong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617031/ https://www.ncbi.nlm.nih.gov/pubmed/34824248 http://dx.doi.org/10.1038/s41467-021-27210-x |
Ejemplares similares
-
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
por: He, Yonghan, et al.
Publicado: (2020) -
A selective BCL-X(L) PROTAC degrader achieves safe and potent antitumor activity
por: Khan, Sajid, et al.
Publicado: (2019) -
Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells
por: Jia, Yannan, et al.
Publicado: (2023) -
PROTACs are effective in addressing the platelet toxicity associated with BCL-X(L) inhibitors
por: Zhang, Peiyi, et al.
Publicado: (2020) -
Targeting BCL-XL in fibrolamellar hepatocellular carcinoma
por: Shebl, Bassem, et al.
Publicado: (2022)